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INTRODUCTION 
Pseudorables virus is a neurotropic herpesvirus natural to swine 
which causes an acute, often fatal infection of young swine, lower 
mortality but high morbidity in older swine, and abortion and 
stillbirths in pregnant sows (12, 62, 173). Cattle, sheep, goats, 
dogs, and cats are also susceptible and in these species the disease is 
uniformly fatal (12, 42, 62, 82). 
Since the early 1970s, the incidence of pseudorabies has signifi­
cantly increased in the U.S. (39, 56, 62). The swine industry is very 
interested in measures that will reduce losses to the disease. Vac­
cination can be an effective method of controlling the disease in areas 
with a high incidence of pseudorabies (40, 109, 171). Attenuated 
vaccines that are greatly reduced in virulence for swine are 
commercially available, but these vaccines may retain considerable 
virulence for other species (98, 174). 
Recently the role of the pseudorabies virus-coded enzyme, 
thymidine kinase, in determining neurovirulence has become recognized 
(169). The objectives of this study were to: 
1) isolate a thymidine kinase-deficient mutant from a virulent 
PrV parental strain; assess the mutant for reversion to TK^; 
and assess the mutant for virulence in mice and young swine; 
2) determine the TK phenotype and virulence for mice of the 3 
federally licensed modified live vaccine strains and 2 field 
isolates; 
2 
3) conçare the kinetic behavior of TK from the vaccine strains 
and field isolates; 
4) evaluate the TK." mutant for effectiveness as a pseudorabies 
vaccine in mice and swine; and 
5) compare the migration patterns of restriction endonuclease-
digested DNA of the strains included in the study. 
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LITERATURE REVIEW 
Introduction 
In 1902, the Hungarian veterinarian Aladar Âujeszl^ was the first 
to describe in the scientific literature a rapidly fatal disease 
(pseudorabies), occurring naturally in the bull, cat and dog, and which 
could be experimentally transmitted to rabbits (6). Von Ratz produced 
the disease in swine, in 1914 (177). The disease was referred to as 
infectious bulbar paralysis in the early literature, but in Europe the 
accepted name for the infection became Aujeszlqr's disease. 
In the United States, a similar fatal disease of cattle, known as 
"mad itch" had been described in agricultural journals numerous times 
during the 19th century (68). In 1931, Shope concluded from experi­
mental data that Aujeszky's disease, or "mad itch," and the disease of 
swine, pseudorabies, were caused by the same filterable virus (155). 
Shope further concluded that the virus is contagious among swine, that 
cattle contract the disease from swine through abrasions of the skin, 
and that the virus is not normally transmitted from cow to cow (156, 
157). 
Pseudorabies virus 
Pseudorabies virus (PrV) (suid herpes virus 1) is classified as an 
alpha-herpes virus, in the same subfamily as herpes simplex virus (USV) 
types 1 and 2, equine herpesvirus type 1, and bovine herpesvirus type 2 
(145). Ben-Porat and Kaplan recently presented an extensive review of 
the biochemical and genetic properties of PrV (16). The mature virion 
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Is approximately 180 nm in diameter and consists of a viral capsid of 
110 nm diameter surrounded by a double- or triple-
layer, lipid-containing membrane (34, 144). 
The viral genome is a double-stranded DNÂ molecule of approxi­
mately 90 X 10^ daltons molecular weight (MW) (147). Structural 
analysis of the genome reveals a long unique (U^) sequence with a MW of 
65 X 10^, an internal inverted repeat sequence (IR) with a MW of 10 x 
10^, a terminal repeat (IR) sequence (MW 10 x 10^), and a short unique 
(Ug) sequence (MW 6 X 10^) located between the IR and IR regions (17, 
161). Restriction enzyme cleavage maps (Figure 1) were provided by 
Ben-Porat and Kaplan (16). 
Considerable biological, biochemical and genetic similarity has 
been demonstrated between FrV and HSV (15, 18, 84, 142), suggesting 
evolution from a common ancestor, and the utility of applying knowledge 
of the one virus toward better understanding of the other. 
Clinical signs 
Clinical signs associated with pseudorabies are variable and are 
influenced by the host species (42, 47, 51, 56, 82, 108), the degree of 
exposure (10), the route of exposure (141, 150), the age of the host 
(12, 27, 56, 71), and the strain of virus (12, 138, 139). 
In cattle, sheep, dogs, cats, rats, and mice the clinical signs 
are primarily pruritis, convulsions, paralysis and rapid death, re­
flecting an acute infection of the central nervous system (CMS). 
Self-mutilation by biting, scratching, and rubbing of the skin against 
objects is common. 
Figure 1. Restriction endonuclease cleavage maps of PrV DNA. Line A; Pst I digest; line B: 
Bam HI digest; line C: Kpn 1 digest; line D: physical model of the PrV genome 
showing l:he location of the unique long (U^), unique short (Ug), inverted repeat (IR) 
and termJ'.nal repeat (TR) sequences. From Ben-Porat and Kaplan (16) 
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In swine, clinical signs are greatly influenced by age. In 
piglets less than 2 weeks of age, mortality can exceed 80%. Clinical 
signs reflect acute CNS infection: tremors, convulsions and coma 
followed by death are typical. In older swine, the CNS is often 
affected, but to a lesser degree. Incoordination, depression, and 
occasionally posterior paralysis occur. Common features in older swine 
are pyrexia, anorexia, sneezing and dyspnea. Vomiting, excessive 
salivation, blindness and pruritis are occasionally observed in swine 
infected with PrV. In mature swine, morbidity is often high but 
mortality is usually low; clinical disease can be mild and adult swine 
may experience subclinical infection (12, 56, 62, 130). 
Pathogenesis 
In swine, the natural route of exposure is by inhalation or 
ingestion of the virus (12, 150). Evidence has also been presented 
suggesting that some strains of PrV may be transmitted sexually (26, 
52, 78). 
After inhalation or ingestion of PrV, the virus replicates in the 
nasopharyngeal mucosa and tonsils. The virus next enters the 
lymphatics and can be isolated from draining lymph nodes. Limited 
evidence indicates that PrV may invade leucocytes, although detection 
of viremia is rare (12, 32, 182). 
From the nasal and pharyngeal mucosa PrV enters the CNS, in which 
the principal histopathologic changes are seen (32, 41, 130). Neuro-
pathological lesions associated with pseudorabies are a non-suppurative 
encephalitis, mild myelitis, and ganglioneuritis. Marked perivascular 
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cuffing is also observed. PrV can be isolated from the medulla and 
pons 24 hrs after infection. PrV may spread from the CNS to the spinal 
ganglia and femoral nerves (141). 
PrV may also invade the lung, liver, and spleen from which the 
virus can occasionally be isolated and in which necrotic foci have been 
observed in histopathologic studies (32, 56, 150). Tropism for the 
lung is variable among strains; pneumonia can result from PrV infection 
(9) but significant pathologic changes in the lung are not caused by 
all strains (141, 150). 
Infection of boars and pregnant sows céui lead to serious losses in 
breeding herds. In utero infection with PrV can result in fetal 
mummification, abortion, stillbirths, and the birth of weak piglets 
(33, 57, 96, 173, 183). Infection of boars can result in testicular 
degeneration and infertility (67, 77, 106). 
Similar to HSV (91), PrV has been shown to cause persistent and 
latent infections in its natural host. Sabo and Rajcani recovered PrV 
from explanted tonsils, cervical lymph nodes, nasal mucosa and 
gasserian ganglia removed from swine between 160 and 181 days post-
inoculation (149). Other workers have reported isolation of PrV from 
latently Infected swine (19, 22, 36, 65, 175). Gutekunst detected 
latent PrV DNÂ. in trigeminal ganglia from 5 out of 6 swine, 7 months 
after exposure (63). 
Epidemiology 
Shope recognized that pseudorabies was a natural infection of 
swine, from which the virus is occasionally transmitted to other 
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species (156, 157). Virus is present in nasal secretions of infected 
pigs during the acute phase of infection (111, 119, 156) and may also 
be shed by recovered swine (36, 128). Although susceptible to 
pseudorables, cattle, dogs, and cats have not been shown to transmit 
the disease once infected (42, 128). Rodents have been suspected to 
play a role in spreading PrV (12, 118, 127, 158) and raccoons may be 
able to transmit the virus (83); however, these species are not 
considered to be a significant factor in the spread of PrV (12, 118, 
184). Although susceptible to Infection, these species do not shed 
virus, once infected. 
The principal reservoir of PrV is the latently Infected, recovered 
pig. The carrier pig is believed to be the source of infection for 
numerous outbreaks of pseudorables (12, 74, 76, 97, 128, 170). 
Infection of swine with PrV results in both humoral and cell-
mediated immune responses (4, 11, 66, 121, 136, 181). Infection of 
nonimmune swine results in the production of neutralizing antibody (NA) 
in the serum, generally detectable at low levels at 7 days post inocu­
lation (DPI) (66, 112, 121, 136). Neutralizing antibody titers 
increase dramatically through 14 DPI and peak at 35 DPI (113). 
Although NA undoubtedly plays an important role In immunity to 
PrV, cell-mediated immunity (CMI) may also play a major role in re­
covery from infection. Cell-mediated immunity to PrV has been 
demonstrated in the pig after infection (4, 11, 181), but detailed 
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information on the role of QH in recovery from PrV infection is not 
available. 
Extensive studies on the immune response of mice to ESV has 
revealed a predominant role for CMI in recovery from infection (35, 86, 
125). Cytotoxic T lymphocytes (CTL) from infected animals specifically 
lyse syngeneic cell cultures infected with HSV (81, 135, 146), and may 
play a significant role in recovery from herpes virus infection. Other 
experiments with mice indicate that lymphocytes bearing antigens common 
to T-helper cells and delayed hypersensitivety T cells may play an even 
greater role than CTL in the CHI response to ESV infection (126). 
Vaccination 
Numerous vaccination studies with PrV have appeared in the litera­
ture. Both inactivated and modified live virus (MLV) vaccines are 
commercially available in many countries and are effective in 
preventing mortality and decreasing morbidity (40, 75, 109, 114, 115, 
132, 134, 148, 160, 176). 
The inactivated vaccines normally require 2 injections to induce 
protective immunity and the MLV vaccines are generally effective after 
one inoculation. None of the vaccines evaluated to date has prevented 
Infection by virulent challenge virus, and challenge virais may be shed 
by previously vaccinated swine (114, 115, 148). Virulent challenge 
virus may also establish latent infections in previously vaccinated 
animals (123, 176). 
11 
Modified live virus vaccines 
Bartha was the first to report, in 1961, the isolation of a PrV 
strain of attenuated virulence (7). Bartha selected a stable small-
plaque mutant from a virulent parental strain exhibiting a mixture of 
large and small plaques in cell culture. 
The Bartha strain has been used successfully as a MLV vaccine to 
prevent serious illness in challenged swine (8, 38, 114, 176). The 
protection conferred by the Bartha strain is not complete; vaccinated 
and challenged animals exhibit clinical signs of a mild infection, 
characterized by fever, some sneezing, reduced appetite, and dullness. 
A second attenuated strain was reported by Skoda et al. in 1964 
(159). This strain, derived from the Bucharest strain and designated 
BUK, had been passaged up to 621 times in chick embryo chorioallantoic 
(CEC) membranes. The BTJK strain retained a large plaque morphology in 
cell culture and was greatly reduced in virulence for swine at passages 
above 336 in CEC membranes, although the strain retained virulence for 
rabbits. 
The BTJK strain has subsequently been widely used as a MLV vaccine 
(75, 80, 148, 160). As with the Bartha strain, BUK does not induce an 
absolute immunity. Vaccinated swine may still be infected with a 
challenge strain, and may experience a mild infection. 
Studies indicate that neither the Bartha strain (114, 176) nor the 
BDK strain (119) are excreted by vaccinated swine. Jamrichovâ and 
Skoda (80) recovered virus from the site of inoculation, regional lymph 
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nodes, and Che CNS of pigs inoculated with the BUK strain» indicating 
limited replication in the pig. 
Although the Bartha and BUK strains do not produce clinical 
disease in swine, Piatt et al. (138, 139) reported fatal infections in 
rabbits and mice with both strains. Other reports of fatal infections 
caused by FrV MLV in non-swine species have appeared in the literature. 
Muhm and Beard (124) reported deaths in cats, dogs, rabbits and 
chickens inoculated with a commercial MLV vaccine strain. Konig (198) 
and Van Alstine et al. (174) reported fatal infections in sheep caused 
by commercial MLV vaccines, accidentally Introduced by the use of 
contaminated syringes and needles. 
Thymidine kinase 
In 1983 Tenser et al. (169) reported that the expression of a 
PrV-coded enzyme, thymidine kinase (TK), was necessary to establish an 
acute trigeminal ganglion infection in mice. Mice were inoculated 
comeally with either TK^ or TK~ PrV, and the ability of the virus to 
replicate at the site of inoculation and in the trigeminal ganglia was 
measured. Both TK^ and TK strains replicated to high titers in ocular 
tissues, but only TK* replicated to high titers in the trigeminal 
ganglia. Only trace amounts of TK PrV were detected in trigeminal 
ganglia. Mortality rates for mice receiving 1 X 10^ plaque-forming 
units (PFU) or greater of TK* or TK PrV were 100% and 0%, respec­
tively. 
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Lomniczl et al. (107) confirmed the role of PrV TK In determining 
neurovirulence. TK~ mutants of the Norden^ (derived from BUK), Bartha, 
and Kaplan (Ka) PrV strains did not produce fatality in mice or in 
one-day-old chicks. 
Thymidine kinase is an enzyme that functions to salvage thymine as 
a substrate for DMA biosynthesis. Fre-formed deoxythymidine is 
phosphorylated by TK to form deoxythymldlne monophosphate (dTMP), a 
necessary precursor of DNÂ. TK generates dTMP from free thymidine, 
providing an independent pathway distinct from the cellular thymidylate 
synthetase pathway (151). 
Increased levels of TK are observed in various tissues during DNA 
synthesis (24, 95, 164, 165, 185), but the TK level is very low in 
differentiated nerve tissue (3, 102, 185). Mutant cell cultures 
lacking TK activity can be isolated by prolonged propagation in medium 
containing 5-bromo-2 '-deoxyurldlne (BUdR) (87, 88). Cell cultures 
encoding normal levels of TK, which are grown In the presence of BUdR, 
have a greatly reduced growth rate and are eventually overgrown by 
BUdR-resistant cells lacking TK activity, which have a normal growth 
rate (79, 88). 
Numerous herpesviruses in addition to PrV have been shown to 
induce a virus-coded TK in infected cells, Including USV (43), 
varicella-zoster virus (129), marmoset herpesvirus (89), herpesvirus 
^Norden Laboratories, Inc., Lincoln, NE. 
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salmi ri (73), bovine herpesvirus type 1 (180) and equine herpesvirus 
type 1 (1). 
The relationship betssen HSV TK phenotype and neurovirulence was 
first described by Field and Wildy (48), who compared the virulence of 
two TK mutants with their TK* parental strains. Three-week-old BALB/c 
mice were inoculated either in the ear pinna or intracerebrally (IC) 
with TK or TK HSV. The TK mutants were greatly reduced in virulence 
by the IC route and both TK mutants failed to produce clinical disease 
I 
following peripheral inoculation. The TK~ mutants did replicate 
locally in the ear pinna but to a reduced extent relative to the TK* 
parental strains, and were cleared from the tissue more quickly. 
Tenser et al. (167) and Tenser and Dunstan (166) similarly re­
ported the inability of TK HSV to replicate in the trigeminal ganglia 
of mice after corneal inoculation, in contrast to TK* HSV which did 
replicate to high titer in the ganglia. Similarly, a TK* revertant of 
a TK mutant reached titers similar to wild-type TK* HSV. The TK 
mutants did, however, reach similar titers in ocular tissue, which 
supported the hypothesis that HSV TK plays an important role in in­
fections of the sensory ganglia. 
Numerous studies have further confirmed the role of HSV TK in 
determining neurovirulence (13, 14, 46, 50, 58, 59, 92, 93, 110, 140). 
Price and Khan (140) reported that viral antigen was absent in superior 
cervical ganglia in mice infected with TK~ HSV, even after immuno­
suppression by cyclophosphamide or prior treatment with the neurotoxin 
6-hydroxydopamine, both of which enhanced infection with TK* HSV. The 
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TK strain did, however, replicate at the site of inoculation, 
providing further evidence that HSV TK facilitates acute, productive 
infections of neurons. 
Ben-Hur et al. (14) demonstrated that TK~ HSV produced greater 
than 50% mortality in 4-day-old mice inoculated corneally with 10^ 
PFU/milliliter (ml). At 10 days of age, mice inoculated similarly were 
not affected by the same exposure, indicating that age is a factor in 
susceptibility to infection by TK HSV. In contrast, the mortality 
rates in 4-day-old and 10-day-old mice inoculated with TK* HSV were 
similar, and decreased only slightly for 28-day-old mice, indicating 
that maturation of the immune system does not explain the significant 
age-related resistance to TK HSV. It has been demonstrated that TK 
activity in the cerebellum of rats reaches a peak on day 5 or 6 after 
birth, then declines to negligible levels by week 3 (164, 179, 185). 
It was concluded that the large increase in mortality in 4-day-old mice 
is probably associated with high levels of cellular TK that occur in 
developing brain tissue. 
In an experiment with cyclophosphamide-treated mice, Gordon et al. 
(60) produced a fatal encephalitis by inoculation of a TK HSV intra-
cranially. Histological examination revealed that non-neural glial 
cells were permissive and supported replication of HSV TK virus, 
indicating that a functional immune system plays a role in resistance 
to infection by TK HSV. 
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Vaccination with IK HSY 
Marcialis (120) isolated a 5-iodo-2'-deoacyurldine (lUdR) resistant 
HSV mutant which had greatly reduced virulence for mice. The mutant 
was used to vaccinate mice and rabbits and was effective in protecting 
mice from paralysis and death and rabbits from conjunctivitis, 
keratitis and encephalitis after challenge with virulent HSV. 
Field and Wildy (48) challenged mice previously inoculated with 
TK" HSV and demonstrated resistance to challenge with 100 LD^g of the 
HSV CI strain 2 to 3 months after Immunization. 
The results of other studies have confirmed the efficacy of TK 
HSV strains to protect mice from severe clinical infection and death 
when challenged with virulent HSV (92, 93, 94, 110). 
Assays for thymidine kinase activity 
TK activity may be determined in cytoplasmic lysates by measuring 
14 3 
the phosphorylation of C-thymidine (186), H-thymidine (151) or 
125 [ I]iododeoxyuridine (61). The negatively charged product (dTMP) is 
separated from the uncharged substrate by binding to DEAE-cellulose 
paper (151). The kinetic behaviors and substrate specificities have 
been reported for TK from cellular cytoplasm (23, 103), mitochondria 
(23, 103, 104), marmoset herpesvirus (104) and herpes simplex virus 
(29, 99, 100). 
Â thymidine plaque-autoradiography assay was recently developed 
(168) in which HSV was grown in TK cells under methylcellulose overlay 
until visible plaques had formed. The overlay was removed and medium 
containing ^^C-thymidine was added, followed by Incubation at 37 C for 
17 
+ 14 6 hours. TK virus incorporated the C-thymidine, which caused film 
darkening when the culture dishes were exposed to x-ray film. TK~ 
14 -
virus does not incorporate C-thymidine, and TK plaques do not cause 
film darkening. 
Selection of TK herpesviruses 
Numerous nucleoside analogs have been identified which react 
preferentially with herpesvirus TK and provide a basis for anti-
herpesvirus chemotherapy (5, 30, 31, 54). The herpesvirus TK 
phosphorylates a nucleoside analog to the monophosphate form which is 
further converted to the triphosphate form. Nucleoside analog 
triphosphates inhibit viral replication by direct interaction with the 
viral DNA polymerase enzyme or by incorporation into viral DNA., which 
functions abnormally (30, 31, 45, 101, 153). Strains of HSV deficient 
in TK have been isolated by growing virus in the presence of increasing 
concentrations of BUdR (43, 163), acyclovir (49), and arabino-
furanosylthymine (Ara-T) (167). Strains of PrV deficient in viral TK 
have been isolated by selection in the presence of Ara-T (107, 169). 
Revertant TK^ virus can be selected in TK cell cultures in the 
presence of hypoxanthlne, amethopterin, thymidine and glycine (163) or 
methotrexate,^ thymidine, adenosine, guanosine and glycine (28). 
Methotrexate (amethopterin) or aminopterin each block de novo dTHF 
biosynthesis. In the presence of methotrexate or aminopterin, the only 
^Lederle Parenterals, Inc., Carolina, F.R. 
18 
source of dTMP for DNA synthesis is by the phosphorylation of free 
thymidine by TK. TK cells cannot convert thymidine to dIMP; 
therefore, only TK^ virus can replicate under such selective 
conditions. 
Restriction enzyme analysis 
Migration patterns in electrophoretic gels of restriction 
endonuclease digested PrV DNA have been compared by several 
investigators (53, 55, 70, 131, 137). Considerable variation existed 
among field isolates, but it was also noted that certain regions of the 
genome gave rise to higher frequencies of variability. Greater 
variability was associated with fragments from the inverted repeat 
sequences and regions close to the 5'end of the genome. Similar 
molecular weight changes in restriction fragments have been observed in 
other herpes viruses (2, 69, 162). 
The Bartha and Norden (BUK) strains were shown to contain a major 
deletion in their genomes, approximately 2.7 x 10^ daltons, mapping in 
the unique short region. The deleted sequences contained a genetic 
determinant of virulence distinct from TK (107), but the nature of the 
gene product and its role in virulence has not been identified. 
Humoral antibody determination 
Various methods have been developed to detect antibodies to PrV in 
sera from vaccinated or infected swine. The virus neutralization test 
(72) is sensitive and is a good method for quantitative antibody 
determinations. In recent years, the enzyme-linked immunosorbent assay 
19 
(ELISÂ) has become widely used as an alternative to the virus 
neutralization test for the detection of antibodies to PrV (121, 172) 
Other methods which have been reported for detecting antibodies 
PrV include the microimmunodlffusion test (64), indirect solid-phase 
mlcroradioimmunoassay test (85) and complement fixation test (44). 
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MATERIALS AND METHODS 
Media 
Growth medium 
Growth medium (Ql) for cell cultures consisted of Eagle's minimal 
essential medium (MEM)^ with Earle's salts and 2 L-glutamine 
supplemented with 10% fetal calf serum (FCS). Fifty mg of gentamicin 
sulfate^ were added to each liter prior to use. 
Maintenance medium 
Maintenance medium (MM) consisted of MEM with Earle's salts and 
2 mM L-glutamine supplemented with 2% FCS, 50 mg gentamicin sulfate, 
2 3 100,000 units penicillin G , 0.1 g strepton^cin sulfate and 2.5 mg 
4 
amphotericin B per liter. 
Swab elution medium 
Swab elution medium was the same as MM with the exclusion of FCS. 
^GIBCO; Life Technologies, Inc., Chagrin Falls, OH. 
^Eli Lilly & Co., Indianapolis, IN. 
3 
Pfizer Laboratories, New York, NY. 
4 Fungazone; E. R. Squibb & Sons, Princeton, NJ. 
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Agarose overlay medium 
Agarose overlay médium (AOM) was prepared with equal parts of 
2Z Qi and 1.6% liquefied agarose^. The agarose was liquefied by 
autoclaving at 15 psi for 15 minutes and was cooled to 45 C. 
Carboxymethyl cellulase overlay medium 
2 Carbo^qnnethyl cellulose (CMC), medium viscosity, was added co 
distilled H^O (1 g/100 ml), autoclaved at 15 psi for 15 minutes, cooled 
to room temperature, then placed at 4 C overnight. The liquefied CMC 
was added to 2X GM in equal parts and was warmed to 37 C prior to use. 
Cell Cultures 
MDBK cells 
The Madin-Darby bovine kidney (MDBK) cell line was used for virus 
propagation, titration of virus, and plaque cloning of virus. MDBK 
2 3 
cells were propagated at 37 C In 75-cm flasks. Confluent monolayers 
were treated with trypsin-versene solution (TVS) (Table 1), diluted 
4 2 
1 to 4 in GM and dispensed into flasks, 6-well plates or 850-cm 
3 
roller bottles . 
^SeaKem ME; Marine Colloids Division, FMC Corp., Rockland, ME. 
2 Sigma Chemical Co., St. Louis, MO. 
3 Falcon; Becton Dickenson & Co., Oxnard, CÂ. 
4 
Linbro; Flow Laboratories, Hamden, CT. 
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Table 1. Trjpsln-versene solution 
Na^EDTA^ 
NaCl 
KCl 
Glucose 
NaHCO^ 
Trypsin^ 
Phenol Red 
Distilled H2O 
Adjust pH to 7.3; filter 
sterilize, and store at -20°C 
0.2 g 
8.0 g 
0.4 g 
1.0 g 
0.58 g 
0.5 g 
0.2 mg 
q.s. to 1000 ml 
Wisher Scientific; Fair lawn, NJ. 
^Dlfco Laboratories, Detroit, MI. 
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LMIK" cells 
— 1 2 T.MTG~ cells (88) were propagated in GM in 75-cm flasks. 
Monolayers were trypsinized, diluted 1 to 3 in GM and dispensed into 
2 plastic flasks or 15 x 60 mm tissue culture dishes . The culture 
dishes containing Q1 were incubated overnight prior to seeding. 
All six-well plates and 15 x 60 mm dishes were maintained at 37 C 
in a humidified chamber with 5% CO2 atmosphere. 
Viruses 
Field strains 
The Indiana-Funkhauser (IN-Fh) strain of PrV (152) was isolated in 
3 1975 and was received at the 16th cell culture passage, and was 
passaged once in MDBK cells. 
The NVSL 85-12 strain was isolated in 1984 from a pig and was 
4 
received at the 3rd cell culture passage, and was passaged twice in 
MDBK cells. 
^Obtained from Dr. S. Kit, Baylor University, Houston, TX. 
^LDX; Lab-Tek, Naperville, IL. 
3 Obtained from Dr. E. C. Pirtle, National Animal Disease Center, 
Ames, IÂ. 
^Obtained from Dr. H. T. Hill, Virus Diagnostic Laboratory, Iowa 
State University, Ames, lA. 
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Vaccine strains 
12 3 
The modified live PrV vaccine strains ' * , In the lyophlllzed 
state, were obtained commercially, were reconstituted as directed and 
then were passaged once In MDBK cells. 
Virus propagation 
Confluent monolayers of KDBK cells were inoculated with virus at a 
multiplicity of 0.01 to 0.1 plaque forming units (PFU) per cell. Virus 
was allowed to adsorb to the cells for 60 minutes at 37 C. Twenty ml 
2 
of GH were added to each 75-cm flask after Inoculation. 
Virus Infected cells were incubated at 37 C until 100% cytopathlc 
effects (CPE) was observed. Cell debris was removed by centrifugation 
at 500 X g for 10 minutes and the virus suspension was divided into 
aliquotes in plastic tubes and was frozen at -70 C. 
Virus plaque titration 
Ten-fold dilutions of virus stocks were prepared in MEM. 
One-tenth ml of diluted virus was adsorbed to each of 3 wells of 
confluent MDBK cells grown in 6-well plates. Virus was adsorbed for 
^PR-Vac; Norden Laboratories, Inc., Lincoln, NE. 
^seudoVax; Pitman-Moore, Inc., Washington Crossing, NJ. 
3 Pseudorabies Vaccine; BioCeutic Laboratories, Inc., St. Joseph, 
MO. 
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60 minutes at 37 C, at which time 2 ml of ÂOM were added per well. 
The plates were incubated at 37 C in 5Z CO^ for 72 hours and then the 
cells were fixed and stained with 0.1% crystal violet in 10% formalin. 
Plaque-passaging of virus 
Well isolated viral plaques under AOM were picked with a sterile 
micropipette tip and were eluted in 2 ml of 01. The eluted virus was 
"plaque titrated" as ahove. 
Isolation of TK5A1 
IN-Fh FrV was grown one passage in HDBK cells and GU containing 
5 iig/ml of 5-bromo-2 ' -deoxyuridine (BUdR). Â second passage was made 
in the presence of 10 yg/ml BUdR. The virus suspension was plaque 
titrated under ACM containing 10 yg/ml BUdR. Several large plaques 
were picked and passaged once with BUdR at 100 yg/ml. Each clone of 
BUdR-resistant virus was passaged twice more in the presence of GM with 
100 yg/ml BUdR and 200 yg/ml of arabinofuranosylthymi ne (Ara-T).^ 
Three clones of BUdR and Ara-T resistant virus were plaque 
passaged twice at 38.5 C to insure against temperature-sensitive 
mutants. Several plaques were picked, passaged once in MDBK cells and 
Ql, and then were assayed for TK activity by thymidine plaque auto­
radiography. 
^Sigma Chemical Co., St. Louis, MO. 
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The clone identified as IK5A1 vasr judged to be deficient for TK 
activity and a stock culture was prepared by one additional passage in 
HDBK cells. 
Assay of IK5A1 for reversion to TK* 
A 75-cm confluent monolayer of T.MTK cells (4 x 10 cells) was 
inoculated with 1.2 x 10^ PFU of TK5A1 PrV. Virus was adsorbed at 37 C 
for 60 minutes, the inoculum was removed, and the monolayer was washed 
once with MEM. The inoculum was replaced with 20 ml of GM containing 
5 X 10~^ M hypoxanthine, 5 x 10 ^ M methotrexate,^ 1 x 10 ^ M thymidine 
and 1 X 10 * M glycine (HMTG). The flask was incubated at 37 C for 3 
days and was observed daily for CPE. On day 3, the flask was frozen at 
-70 C and then was thawed to rupture cells. Cell debris was removed by 
centrifugation at 1000 x g for 10 minutes, and 1 ml of supernatant was 
used to inoculate a second LMTK monolayer. The second, and a third, 
blind passage in the presence of HMTG was conducted as above. One ml 
of supernatant from the third passage with HMTG was used to inoculate a 
2 75-cm culture of MDBK cells. The inoculum was adsorbed at 37 C for 60 
minutes, the inoculum was removed, and the monolayer was washed with 
MEM. The inoculum was replaced with 20 ml of GM. The flask was 
observed for CPE for 6 days. 
As a control, 4 x 10^ PFU of NVSL 85-12 PrV was passaged 3 times 
in LMTR~ cells in the presence of HMTG, followed by one passage in MDBK 
^Lederle Parenterals, Inc., Carolina, P.R. 
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cells with GM as above, with the exception that flasks were frozen when 
100% CPE was observed. 
To determine lAether tksai reverts to TK^ under nonselective 
conditions, TK5A1 was passaged 10 times in HDBK cells in the presence 
of Ql. The TK phenotype of virus in the 10th passage supernatant was 
determined by thymidine plaque autoradiography. 
Thymidine Kinase Assays 
Thymidine plaque autoradiography 
The procedure for thymidine plaque autoradiography has been 
described previously (168). LHTK cells grown in 15 x 60 mm dishes 
were inoculated with 0.1 ml of virus suspension diluted to contain 50 
to 150 PFU. Virus was adsorbed for 60 minutes at 37 C and then plates 
were overlaid with 5 ml CMC overlay medium. Dishes were placed at 37 G 
in 5% CO^ for 72 hrs. The CMC overlay was decanted and the cell 
monolayer was washed once with MEM, followed by incubation for 6 hours 
with 2 ml MEM containing ^^C-thymidine (0.5 pCi/ml; 55 mCi/mmol)^. The 
medium was removed and cells were fixed and stained with 0.1% crystal 
violet in 10% formalin. Excess crystal violet was removed by 3 washes 
with SgO. The plates were air dried overnight. 
^Amersham Corp., Arlington Heights, XL. 
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The rims of the plastic dishes were removed with scissors, and 
dish bottoms were placed in an X-Omatic film cassette,^ and the cell 
monolayer was exposed to XAR-5 x-ray film^ for 3 to 7 days at room 
temperature. After exposure, the film was developed, then was 
photographed while illuminated by a light box. 
Thymidine kinase kinetic assay 
The procedure of Zâvada et al. (186) was adapted for determining 
PrV TK activity in cytosol extracts. Confluent monolayers of LHTK" 
2 
cells grown in 75 cm flasks were infected with FrV at a multiplicity 
of infection (MOI) of 5-10 PFU/cell and incubated for 18 hours at 37 C. 
Supernatant was removed, and monolayers were washed twice with 
Tris^-buffered saline (TBS) (0.14 M NaCl, 0.01 M Tris-HCl, pH 7.5). 
The cells were scraped free with a rubber policeman into 5 ml of TBS 
3 
containing 5 yM thymidine and 2 mM dithiothreitol. The cells were 
pelleted at 500 x g for 10 minutes and were washed once in cold lysis 
buffer (LB) (O.OIM Tris-HCl, 2 mM dithiothreitol, 5 pM thymidine). 
The cells were pelleted, resuspended in 1 ml LB and allowed to swell on 
ice for 10 minutes, followed by disruption in a Bounce homogenizer 
cooled to 4 C. One-tenth volume 1.4 M NaCl was added, and the cell 
^Eastman Kodak, Rochester, NY. 
2 Trizma base; Sigma Chemical Co., St. Louis, MO. 
3 Sigma Chemical Co., St. Louis, MO. 
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debris vas pelleted at 10,000 x g for 10 minutes. The supernatant was 
further centrlfuged at 105,000 s g for 1 hour at 4 C. The supernatant 
containing PrV TK was frozen at -70 C, in 100-ul aliquots. 
For each enzyme reaction mixture, a 25-ul volume of cell extract 
was added to 62.5 ul of reaction buffer (100 mM Tris-HCl, 10 mM MgCl^, 
10 mM ATP;, pH 8.0), plus 17.5 pi of sterile distilled H^O. Substrate 
(^^C-thymidine^) was prepared in distilled H^O (1:5, 1:10, 1:25, 1:50, 
1:75) and 20 ul were added to each reaction mixture. The reactions 
2 
were conducted in 1.5-ml micro-centrifuge tubes that were Incubated in 
a 37 C water bath for 5, 10, 15 and 20 minute time intervals. 
Reactions were stopped by immersing the tubes in boiling water for 3 
minutes followed by centrifugation at 6500 x g for 1 minute to remove 
denatured protein. For zero-time reactions, the tubes were immersed in 
boiling water immediately after addition of the substrate. Fifty-yl 
volumes of reaction supernatant were spotted onto 2 x 2 cm squares of 
3 DE-81 papers. Papers were air-dried, washed 3 times for 5 minutes in 
4 tbM. ammonium formate 10 minutes in distilled and 10 minutes in 
absolute methanol. The papers were air-dried and placed in 20-ml 
^50 uCi/ml; 55 mCi/mmol; Amersham Corp., Arlington Heights, XL. 
2 
Treff Lab, Tekmar Co., Cincinnati, OH. 
3 
Whatman; VUR Scientific, San Francisco, CA. 
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1 2 
scintillation vials containing 10 ml of scintillant. Each sample was 
counted for 1 minute in a liquid scintillation counter. Hlchaelis 
constants (Km) and maximal velocities (Vmax) for the enzyme reactions 
were obtained from Lineweaver-Burk plots (105). 
Restriction Endonuclease Analysis 
3 Virus production and purification 
2 For each PrV strain, one 850 cm roller bottle containing a 
monolayer of MDBK cells was infected with an HOI of 0.001. The 
inoculum was replaced with 60 ml of Qi after virus had adsorbed for 
2 hrs at 37 C. Infected cultures were incubated at 37 C until 100% CPE 
was observed. The cells were scraped into the medium, pelleted by low 
speed centrifugation, were saved for isolation of nucleocapsids. The 
virus-containing supernatant was layered over 40% sucrose in 0.2 M 
phosphate buffered saline, pH 7.5, and was centrifuged for 1 hour at 
4 25,000 rpm in. an SW28 rotor. The supernatant was discarded and the 
virus pellet was resuspended in 2 ml of TE buffer (10 mM Tris, 1 mM 
EDTA, pH 7.6). 
^Kimble; Owens-Illinois, Toledo, OE. 
2 Ready-Solv HP; Beckman Instruments, Inc., Fuller ton, CÂ. 
3 Viral DNA was extracted according to the method of D. R. Jutting, 
Diagnostic Virology Laboratory, NVSL, Ames, IÂ, personal communication. 
4 
Beckman Instruments, Inc., Fullerton, CA. 
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Nucleocapsid purification 
2 Cells from each PrV-infected 830 cm roller bottle were suspended 
in 2 ml of LCM buffer (3% Na deoxycholate; 30 Tris-HCl, pH 7.3; 123 
mM KCl; 0.3 Na^EDTA; 3.6 mM CaCl^; 3 nM MgCl^; 3% NP-40; 46 pi 
mercaptoethanol/100 ml) and were extracted with 1 ml of Freon 
(l,l,2-trichloro-l,2,2-trifluoroethane). Phases were separated by 
centrifugation at 800 x g for 3 minutes. The upper aqueous phase 
containing nucleocapsids was divided into two portions and each was 
layered over glycerol gradients (13 ml 43% glycerol, 13 ml 3% glycerol, 
in LCM buffer). Nucleocapsids were pelleted by centrifugation for 
1 hour at 23,000 rpm in an SW28 rotor. The pellet was suspended in 
1 ml of TE buffer and was added to the virion suspension from above. 
Extraction of viral DNA 
Extractions were performed according to Van Âlstine et al. (174), 
with slight modifications. To 3 ml of virion and nucleocapsid 
suspension were added 20 yl 20% sodium dcdecylsulfate and 200 ul 
Proteinase (1 mg/ml). Tubes were "vortexed" and then were incubated 
at 37 C for 1 hour. One hundred ul additional Proteinase K were added 
and tubes were incubated until cloudiness disappeared (1 to 3 hours). 
After digestion, DNA.was extracted once with TE-saturated redistilled 
2 phenol, once with chloroform/TE-saturated phenol (1:1) and once with 
^Sigma Chemical Co., St. Louis, HO. 
^Itra-Pure; Bethesda Research Laboratories, Gaithersburg, MD. 
32 
2% isoamyl alchohol in chloroform. One-tenth volume of 3M sodium 
acetate was added and the DNA. was precipitated by the addition of 
2.5 volumes of cold (-20 C) absolute ethanol. Tubes were placed at 
-20 C overnight and the DNA was pelleted by centrifugation at 
12,000 X g for 30 minutes at 0 C. Pellets were air-dried and were 
resuspended in 2 ml of TE buffer. 
Restriction enzyme digestion of DNA 
The procedures for restriction endonuclease digestion of PrV DNA 
and for agarose gel electrophoresis have been reported previously (131, 
137). Approximately 1 ug of viral DNA (30 yl) was digested with 2 pi 
of Bam HI endonuclease,^ Kpn I endonuclease, or Fst I endonuclease. 
The digestion buffer was 50 mM Tris-HCl, 10 mM MgCl2, 1 mM 
dithiothreitol (prepared at 10 X concentration) for Kpn I, or with 50 
nH NaCl for Bam HI. Buffer for Pst I was purchased commercially.^ 
Reaction mixtures were adjusted to 50 ul with distilled H^O and 
were incubated at 37 C for 4 hours. Reactions were stopped by the 
addition of Loening's buffer (30 mM NaH^FO^, 1 mM NagEDTA, 36 mM Tris, 
pH 7.7) containing 60% sucrose and 0.02% bromphenol blue. 
Bacteriophage lambda DNA"** was similarly digested with endonuclease 
Hind III^ as a molecular weight marker (131, 137). 
^Bethesda Research Laboratories, Gaithersburg, MD. 
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Agarose gel electrophoresis 
DNA digests were electrophoresed In 0.8% agarose^ In Loening's 
buffer for 24 hours at 40 volts. The gel was soaked for 1 hour in 
ethidlum bromide (1 yg/ml in distilled H^O), rinsed once in distilled 
2 EgO, and photographed through a Kodak 23A red filter while illuminated 
3 by an ultraviolet light source. The photographic film was Royal X, 
ASA 1250.2 
Animals 
Mice 
4 Five- to six-week-old female CF-1 strain mice were inoculated 
within 2 days of arrival. 
Swine 
Seven-week-old crossbred swine of both sex (25 to 37 lbs) were 
purchased from a breeder at Manilla, lA. All pigs were serologically 
negative for antibodies against PrV. 
^Seakem ME; Marine Colloids Division, FMC Corp., Rockland, ME. 
2 Eastman Kodak, Rochester, NY. 
3 Ultraviolet Transilluminator; LaJolla Scientific Co., Inc., 
LaJolla, CA. 
4 Sprague-Dawley, Indianapolis, IN. 
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Mouse Virulence Test 
Ten-fold dilutions of each PrV strain were prepared in MEM and 
were inoculated into the peritoneal cavity of CF-1 mice, 0.2 ml/mouse. 
Groups of 5 or 10 mice were Inoculated per dilution. Mice were ob­
served for death, 3 times daily, for 14 days post inoculation (DPI), 
with the exception of mice receiving the BioCeutlc strain, which were 
observed for 21 DPI. Mice found dead were incised through the 
peritoneal wall and cranium and were preserved in 10% formalin for 
histopathological examination. 
Vaccination of Mice with TK5A1 
Groups of 10 mice were Inoculated intraperitoneally (IP) with 
0.2 ml volumes of 10-fold dilutions of TK5A1 prepared in MEM. At 
15 DPI, 4 mice from two groups were exsanguinated to obtain serum with 
which to determine the humoral response to vaccination. The remaining 
vaccinated mice and 4 non—vaccinated controls were challenged with 
10 LD^o NVSL 85-12 PRV (0.2 ml, IP). Challenged mice were observed 
for death, daily, for 15 days. At 15 days post challenge (DPC), 4 mice 
from each of 2 groups were bled and all survivors were euthanatized by 
cervical dislocation. 
Vaccination of Swine with TK5A1 
Nine pigs were randomly assigned to 2 groups and were placed In 
separate rooms. Five pigs were inoculated in the neck muscle with 
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2.4 X 10^ PFD of TK5Â1 PrV. The pigs were observed daily for clinical 
signs of disease, rectal temperatures were recorded, and "acal swabs 
were taken for 14 DPI. Ten ml of blood were collected from the vena 
cava at 0, 7 and 14 DPI. 
Four pigs assigned to the non-vaccinated control group were 
similarly bled and rectal temperatures were recorded. Nasal swabs were 
collected at 0, 7 and 14 DPI. 
At 21 DPI, all pigs were swabbed, bled, had rectal temperatures 
recorded, and then were challenged intranasally with 3 X 10^ PFU of 
NVSL 85-12 PrV. Challenge virus was diluted in MEM, and each pig 
received 0.5 ml in each nostril. Rectal temperatures were recorded for 
all pigs, and nasal swabs were taken daily through 14 DPC, or until 
death. Ten-ml blood samples were drawn from surviving pigs at 7, 14 
and 21 DPC. 
Collection of nasal swabs and virus isolation 
Nasal swabs were taken and swabs were placed in 2 ml swab elution 
medium for 45 minutes at 4 C. Tubes were vortexed briefly, swabs were 
removed, and fluids were centrifuged for 10 minutes at 1000 x g. 
One—half ml of supernatant was inoculated onto a confluent monolayer of 
MDBK cells grown in 6-well plates. Plates were incubated at 37 C for 
60 minutes, fluids were removed and 2 ml volumes of MM were replaced. 
Plates were further incubated at 37 C in 5% CO^ for 4 days and were 
examined daily for CPE. Plates containing wells negative for CPE by 
day 4 were frozen at -70 C, were thawed and.0.5 ml of supemate was 
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inoculated onto a fresh monolayer. Second passage plates were observed 
daily for CPE for 4 days. 
Serology^ 
Virus neutralization test 
Serum samples from mice and swine were tested for neutralizing 
antibody to PrV by a method described previously (72). 
Enzyme—It "Iced immunosorbent assay 
Serum samples from swine were tested for antibody specific for PrV 
by the enzyme-linked immunosorbent assay (ELISA) method of Snyder and 
2 
Erickson. 
3 
Histopathology 
Tissue samples from mice preserved in 10% formalin were dehydrated 
in graded alcohol solutions, cleared with xylene, infiltrated with 
paraffin, and were embedded in paraffin blocks for sectioning. Five urn 
sections were cut with a microtome, affixed to slides and stained with 
hematoxylin and eosin. 
^Conducted by Dr. H. T. Hill, Virus Diagnostic Laboratory, Iowa 
State University, Ames, lA. 
2 M. L. Snyder, and G. A. Erickson, Diagnostic Virology Laboratory, 
NVSL, Ames, lA, personal communication. 
3 Conducted by Dr. L. D. Miller, Department of Veterinary 
Pathology, Iowa State University, Ames, lA. 
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RESULTS 
Isolation and Characterization of a Fseudorabies Virus 
Mutant Lacking Thymidine Kinase Activity 
Several clones of the IN-Fh strain of FrV were selected for 
resistance to BUdR and Ara-T. A clone identified as TK5Â1 was 
determined to lack TK activity by thymidine plaque autoradiography 
(Figure 2). Flaques formed by the TK^ parental strain cause film 
14 darkening on X-ray film, (plate 3), because C-thymidine is 
incorporated into DNA during virus replication. Flaques formed by the 
mutant TK5A1 do not darken the film, reflecting the loss of TK 
activity. The mutant replicated as well in MDBK cells as did the 
parental strain (Table 2). The TK5A1 strain was titrated at 37 C and 
at 38.5 C, and titered equally at both temperatures, demonstrating that 
the mutant is not temperature sensitive at 38.5 C. 
Mutant TK5A1 was passaged 10 times in MDBK cells and then was 
examined by thymidine plaque autoradiography for reversion to TK* 
(Figure 3). No plaques possessed a TK* phenotype, indicating that the 
mutant did not revert to TK* at a high frequency. 
• To select for a TK* revertant in the stock culture of TK5A1 FrV, 
1.2 X 10^ FFU of the mutant were inoculated onto LMTK cells and 
passaged 3 times in medium containing HMTG. No virus was recovered 
from 1 ml of the 3rd blind passage supemate. In a preliminary experi­
ment, 2 X 10^ FFU of TK5A1 FrV were similarly tested, and was also 
negative for FrV in the 3rd passage supemate. TK* FrV (NVSL 85-12 
Figure 2. . Thymidine plaque autoradiography assay: A) crystal violet-stained cell monolayers; 
B) x-ray film exposed to cell monolayers. Plate 1: uninfected LHTK cells; Plate 2 i  
TK5A1 strain PrV. Plate 3: IN-Fh strain PrV 
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Table 2. Mortality In mice after Inoculation with virulent and attenuated strains of PrV 
Dilution of Virus (Log^g) PFU/ 
Virus strain 
1 
Titer" 0 -1 -2 -3 -4 -5 -6 -7 ^•>50" 
NVSL 85-12 1.4 X 10® 29/30^ 22/30 6/30 0/10 105 
IN-Fh 3.4 X 10^ 19/20 24/30 3/30 1/30 270 
Norden 7.6 X 10^ 9/10 4/10 0/10 265 
Pltman-Moore 2.7 X 10^ 9/10 4/10 0/10 941 
BloCeutlc 1.1 X 10^ 9/10 5/10 0/10 274 
TK5A1 3.3 X 107 0/15 0/15 >10? 
®PFU/ml. 
^Two-tenths ml Inuculum/mouse. 
calculated by the method of Reed and Muench (143). 
^Number dead/number inoculated. 
Figure 3. Thymidine plaque autoradiography assay: A) crystal violet-stained cell monolayers; 
B) x-ray film exposed to cell monolayers. Plates 1, 2 ,  3 ,  5 ,  6 :  10th passage TK5A1 
PrV. Plate 4: IN-Fh strain PrV 
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strain) replicated well In all passages, and was present In high 
concentration in the 3rd passage supemate. 
Virus Propagation 
Virus stocks were prepared for 2 virulent and 3 commercial attenu­
ated vaccine strains of PrV, and for the IK5Â1 mutant strain (Table 2). 
Virus titers ranged from 7.6 x 10 to 1.4 x 10 PFU/ml. 
TK Phenotype of Selected Virulent and 
Attenuated Strains of PrV 
Two virulent and 3 commercial attenuated vaccine strains were 
determined to have a TK* phenotype by thymidine plaque-autoradiography 
(Figure 4). 
Kinetic Behavior of Thymidine Kinase from 
Selected Strains of PrV 
The kinetic behavior of PrV TK from Infected cell lysates was 
determined for 2 virulent and 3 commercial vaccine strains. 
• Lineweaver-Burk plots (Figure 5) of initial velocity studies were used 
to determine Km and Vmax values for the enzyme from each strain 
(Table 3). Mean Km values ranged from 2.9 to 3.9 uh. Vmax values 
ranged from 1.7 to 6.7. 
Figure 4. Thymidine plaque autoradiography assay; A) crystal violet stained cell monolayers; 
fi) x-ray film exposed to cell monolayers. Plate 1: NVSL 85-12 strain PrV; plate 2: 
uninfected LMTK~ cells; plate 3: IN-Fh strain PrV; plate 4: Norden strain PrV; 
plate 5: Pitman-Moore strain PrV; plate 6: BioCeutic strain PrV 
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Figure 5. Lineweaver-Burk plot of initial velocity data of NVSL 85-12 strain PrV thymidine 
kinase 
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Table 3. Kinetic properties of pseudorables virus thymidine kinase 
Virus Strain Km (ym) 
Km 
Mean Vmax 
Vmax 
Mean 
NVSL 85-12 3.5 
3.3 
3.7 3.5 + 0.20 
3.3* 
4.5 
2.5 3.4 + 1.0 
IN-Fh 4.2 
4.0 
3.3 3.8 + 0.47 
2 .8  
3.0 
3.4 3.1 + 0.3 
Norden 3.0 
2.9 
2.7 2.9 + 0.15 
5.0 
5.2 
2.9 4.4 + 1.3 
Pltman-Moore 3.7 
4.0 
4.0 3.9 + 0.17 
5.5 
5.5 
3.8 4.9 + 1.0 
BloCeutlc 3.2 
2.7 
2 .8  2.9 + 0.26 
6.7 
6.7 
1.7 5.0 + 2.9 
^Reciprocal of counts per minute, x 10 
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House Virulence Test 
Female CF-1 mice were inoculated IF with log^g dilutions of the 6 
FrV strains included in the study, and were observed for death daily. 
The LDgg value for each strain was calculated and used to determine a 
FFD/LD^q value, providing a relative measurement of virulence for the 
mouse (Table 2). The PFU/LD^q values were lower for the 2 virulent 
strains than for the 3 commercial vaccine strains. The value for the 
Fitman-Moore strain was considerably higher than for the other 2 
vaccine strains, but the difference may not be significant because of 
the small number of mice used to determine the LD^^. The TK5Â1 strain 
was avirulent for the mouse, by this route of inoculation. 
Histopathology was performed on selected mice that died after 
inoculation with FrV strains. In addition, 14 mice inoculated with the 
TK5A1 strain were euthanized at 15 DFI and were similarly examined. 
Lesions observed are summarized in Table 4. Adrenal necrosis with 
intranuclear inclusion bodies was the most frequent lesion observed, 
followed by perivascular cuffing in the brain. 
Response of Nice to Vaccination with TK5Â1 FrV 
and Challenge with Virulent Fseudorabies Virus 
Response of mice to vaccination 
No morbidity or mortality was observed in mice vaccinated with 
TK5A1 FrV. Neutralizing antibody titers were either undetectable or 
were very low in mice bled at 15 days post vaccination (DFV) (Table 5). 
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Table 4. Histopathology results from mice dying after inoculation with 
strains of pseudorabies virus 
Virus Adrenal 
Virus Strain Dilution Gland Brain 
IN-Fh 10"^ N 4/15^ C 2/19 
IN-Fh 10-^ N 2/16 G 1/17 
NVSL 85-12 10-^ 0/3 0/3 
BioCeutic 10"^ X 1/4 0/4 
BioCeutic 10-2 0/2 0/2 
Norden 10-1 N 3/4 0/4 
Norden 10-2 N 1/2 0/2 
Pitman Moore 10-1 0/3 0/3 
Pitman Moore 10-2 0/4 0/4 
TK5A1^ - 10° 0/4 0/4 
TK5A1^ 10"! 0/10 C 1/10 
C = Perivascular cuffing 
N = Necrosis and intranuclear inclusion bodies 
X = Necrosis and neutrophilic infiltration but without intranuclear 
inclusion bodies 
G = Ganglion necrosis 
dumber with lesions/number observed. 
^Mice euthanized 15 dpi. 
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Table 5. Neutralizing antibody response in mice vaccinated with TK5Â1 
PrV and challenged with NVSL 85-12 PrV 
Dilution 
Time of Log^. VN 
Mouse Bleeding Vaccine Titre^ 
1 15 DPV^ 0 8 
2 It 0 4 
3 If 0 4 
4 ft 0 4 
5 ft <2 
6 ft <2 
7 II <2 
8 It <2 
9 15 DPC^ <2 
10 It <2 
11 II <2 
12 II <2 
13 II -2 <2 
14 II -2 4 
15 II -2 2 
16 If -2 2 
^Reciprocal of serum dilution. 
^Days post vaccination. 
^Days post challenge. 
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Response of mice to challenge with NVSL 85-12 PrV 
Mortality rates of mice challenged with virulent PrV are shown in 
Table 6. All control mice died, as well as all mice that were 
— A  k S  
vaccinated with TK5A1 PrV diluted 10 and 10 and challenged. Mice 
which were vaccinated with undiluted TK5Â1 or the 10~^ dilution were 
completely protected upon challenge. Mice vaccinated with TK5A1 PrV 
diluted 10 ^  and 10 ^ showed decreasing levels of resistance to 
challenge. 
Selected mice which had been vaccinated and had survived challenge 
were bled at 15 DPC, and were tested for production of neutralizing 
antibody. Virus neutralization titers in these mice were either 
undetectable or were very low (Table 4) 
Response of Swine Vaccinated with TK5A1 PrV 
and Challenged with Virulent Pseudorabies Virus 
Response of swine to vaccination 
Five 7-week-old pigs were inoculated in the neck muscle with 2.4 x 
10^ PFU of TK5A1 PrV. No clinical signs of illness were observed in 
the pigs for 14 DPV. Rectal temperatures recorded from vaccinated and 
control animals are shown in Table 7. Mean temperatures of the vac­
cinated and control groups are shown in Figure 6. Temperatures in the 
vaccinated group were slightly elevated on days 7-9 post vaccination, 
but did not rise above 40.0 C at any time. 
Humoral antibody responses in vaccinated pigs are summarized in 
Tables 8 and 9. Low levels of neutralizing antibody were first 
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Table 6. Mortality of vaccinated mice after challenge with 10 IJ)__ 
of NVSL-85-12 PrV 
^°®10 Mortality 
Vaccine Dilution #dead/#inoculated 
None - 4/4 
TK5A1 undiluted 0/6 
-1 0/6 
-2 1/10 
-3 5/10 
" -4 10/10 
" -5 10/10 
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Table 7. Rectal temperatures of swine after vaccination with TK5A1 FrV 
Pig Number 
_ _ ^ Vaccinated Ncnvaccinated 
Days Post-
Vaccination 41 42 43 44 48 40 45 46 47 
0 39.5 39.8 39.5 39.4 39.8 39.5 39.4 39.4 39.2 
1 39.0 39.5 39.0 39.3 39.5 39.4 39.1 39.1 39.0 
2 ND* ND ND ND ND ND ND ND ND 
3 39.1 39.0 39.1 39.5 39.0 39.5 39.0 39.0 40.0 
4 38.8 39.2 39.0 39.6 39.4 38.8 38.6 38.4 38.8 
5 39.0 39.6 39.0 39.2 39.2 38.5 39.4 38.7 38.8 
6 39.4 39.0 39.2 38.6 39.4 38.8 39.3 39.0 39.6 
7 39.9 39.8 39.3 39.4 40.0 39.4 39.8 38.9 39.1 
8 39.8 39.6 39.4 39.3 39.8 39.2 38.6 39.0 39.2 
9 39.8 39.5 39.3 39.4 39.3 39.0 39.3 39.1 39.4 
10 39.5 39.4 39.0 39.1 39.3 39.1 39.4 39.0 39.2 
11 39.3 39.4 39.0 39.4 39.5 39.3 39.2 39.0 39.4 
12 39.3 39.5 39.1 39.2 39.2 39.4 39.0 38.6 39.3 
13 39.0 39.5 38.9 39.2 39.5 39.1 39.5 39.0 39.1 
14 39.1 39.5 39.0 39.1 39.3 39.0 39.6 39.1 39.1 
^ot done. 
Figure 6. Mean dally temperatures of pigs vaccinated with TK5A1 PrV, and nonvaccinated controls 
$ Nonvaccinated 
A Vaccinated 
D) 
39 
38 
Days Post Vaccination 
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Table 8. Neutralizing antibody titers In pigs vaccinated with TK5A1 
PrV and challenged with virulent pseudorables virus 
Pig Days Post Vaccination Days Post Challenge 
Number 0 7 14 21 7 14 21 
41 Neg Neg 4^ 16 512 256 128 
42 Neg Neg Neg 8 64 128 128 
43 Neg Neg Neg 8 128 256 128 
44 Neg Neg Neg Neg Neg b 
48 Neg Neg 32 32 16 32 256 
4 control 
pigs Neg Neg Neg Neg c ... ... 
Reciprocal of serum dilution. 
^Dled before 14 days post challenge. 
^All control pigs died before 7 days post challenge. 
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Table 9. ELISÂ indices for serum samples from pigs vaccinated with 
TK5A1 PrV and challenged with virulent pseudorabies virus 
Pig Days Post Vaccination Days Post Challenge 
Number 0 7 14 21 7 14 21 
41 0.98* 4.01 4.07 4.56 9.52 8.55 8.72 
42 1.21 2.78 3.57 6.44 9.06 9.02 7.65 
43 0.98 1.68 4.64 6.15 6.22 9.15 7.83 
44 1.26 1.10 1.40 1.16 4.27 ...^ 
48 1.24 2.26 4.17 4.13 4.30 5.89 6.23 
40^ 1.36 1.03 1.38 1.04 ...^ 
45*^ 1.06 1.11 0.81 1.17 
46*^ 2.09® 1.22 0.89 1.43 ... 
47*^ 1.40 1.40 1.31 1.22 ... 
^Index values greater than 1.80 were considered positive for antibody 
against PrV. 
^Died before 14 days post challenge. 
^onvaccinated control. 
^All control pigs died before 7 days post challenge. 
^Nonspecific reaction. 
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detected at 14 DPV in 2 of 5 pigs, and were detected in the serum from 
4 of 5 pigs at 21 DPV. One pig remained seronegative through 21 DPV. 
Three of 3 vaccinated pigs were positive for antibody to PrV at 7 DPV 
by the ELISÂ method. One vaccinated pig was seronegative by ELISÂ 
through 21 DPV. 
The EL1SÂ index for the first bleeding from pig 46 was 2.09 
(Table 9). Infrequently, nonimmune sera will yield index values as 
great as 2.10, due to a nonspecific reaction in the ELISA test. This 
was confirmed as a nonspecific titer by negative indices for subsequent 
bleedings. 
Nasal swabs taken from all pigs were negative for PrV isolation 
through 14 DPV. 
Response of swine to challenge with virulent PrV 
Vaccinated pigs were challenged with virulent PrV at 21 DPV. 
Nonvaccinated control animals were similarly challenged. Rectal 
temperatures recorded post challenge are shown in Table 10, and mean 
daily temperatures are shown in Figure 7. Clinical signs observed in 
PrV challenged swine are presented in Table 11. Fever was defined to 
be temperatures above 40.0 C, and was observed in all animals by 4 DPC. 
Peak temperatures were approximately the same in the vaccinated and 
control groups. Vaccinated animals appeared depressed at 4 DPV and 
exhibited mild dyspnea at 3 DPV, but, with the exception of pig 44, 
experienced only mild clinical signs and recovered quickly. Clinical 
signs in control pigs post challenge were typical for severe 
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Table 10. Rectal teiiq>eratures of swine after challenge with NVSL 85-12 
PrV 
Pig Number 
„ _ . Vaccinated Nonvaccinated 
Days Post-
Challenge 41 42 43 44 48 40 45 46 47 
0 39.0 39.8 39.0 39.0 39.5 38.8 39.6 38.5 39.2 
1 39.1 39.4 39.0 39.1 39.2 39.7 39.6 38.8 39.4 
2 37.4 38.8 38.2 38.8 38.6 39.8 39.5 38.4 40.0 
3 40.2 40.6 40.1 40.8 39.7 40.2 41.0 39.8 40.9 
4 40.5 40.2 41.0 40.8 40.3 40.3 40.5 40.5 41.0 
5 40.0 39.0 40.0 40.6 38.4 40.0 40.8 40.4 41.3 
6 38.8 39.4 39.8 42.0 39.8 M* M 41.0 38.8 
7 38.4 38.0 39.0 40.0 39.4 M H 
8 38.0 38.8 39.0 M 38.8 
9 38.8 39.2 39.0 39.2 
10 39.1 39.8 39.2 39.2 
11 39.6 39.0 39.2 39.6 
12 39.4 38.8 38.7 39.2 
13 40.0 39.0 39.0 39.8 
14 38.8 39.4 39.0 39.1 
^ead. 
Figure 7. Mean daily temperatures of pigs after challenge with virulent PrV 
42 
• Nonvaccinated 
A Vaccinated 
O 40 
39 
38 
,t 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Days Post Challenge 
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Table 11. Clinical signs in swine after challenge with NVSL 85-12 PrV 
Pig Number 
Vaccinated Nonvaccinated Days Post-
Challenge 41 42 43 44 48 40 45 46 47 
0 
1 
2 DT 
3 F F F F FAD 
4 FD FD FD FD FD FAD 
5 B B B FBD B AD 
B 
6 FDA M 
B 
7 ND 
AB 
8 M 
9 
10 
11 
12 
13 
14 
ADT ND D 
FAD AD FAD 
BT T 
FAD FAD FAD 
T B 
FAD FAD FAND 
BT B BT 
M FAND AD 
B B 
M h 
F = Fever D = Depressed 
M = Death B = Dyspnea 
A = Anorexia T = Tremors 
N = Nasal Discharge 
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pseudorables* characterized by CDS involvement, and by severe 
respiratory distress. 
Humoral antibody responses in PrV challenged swine are shown in 
Tables 8 and 9. 
Virus Isolation results from nasal swabs taken from challenged 
swine are summarized in Table 12. Vaccinated animals shed virus from 1 
DPC through 5-7 DPC, with the exception of pig 48, from which viirus was 
isolated intermittently through 12 DPC. Nonvaccinated animals shed 
virus from 1 DPC through day of death. 
Restriction Enzyme Analysis 
Figure 8 shows the Bam HI digests of the six PrV strains included 
in the study. The IN-Fh strain and the TK5ÂI mutant have patterns that 
differ only slightly. The Bam HI L and N fragments of TK5Â1 were 
slightly larger in MW, than those of the parental IN-Fh strain. The 
NVSL 85-12 strain differs from IN-Fh in the N and K or L fragments. 
The Norden and Pitman-Moore strains of PrV differ slightly from each 
other in the Bam HI digest. The stepladder pattern below the D 
fragment has been described previously for the Norden strain, and its 
parental strain, BDK (131). The BioCeutic strain of PrV differs 
considerably from the other strains included in the study when digested 
with Bam HI, indicating that it is not closely related to either the 
other attenuated strains or the 2 virulent strains isolated from the 
midwestem United States. 
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Table 12. Isolation of pseudorables virus from nasal swabs taken after 
challenge 
Days Post-
Challenge 
Pig Number 
Vaccinated Nonvaccinated 
41 42 43 44. 48 40 45 46 47 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
M 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
M 
+ 
+ 
+ 
+ 
+ 
+ 
M M 
(+) Denotes virus isolated. 
(-) Denotes virus not Isolated. 
Dead. 
Figure 8. Bam HI digests of PrV DNA. Lane A: NVSL 85-12 strain; 
lane B: IN-Fh strain; lane C: TK5A1 strain; lane D: Norden 
strain; lane E: Pitman-Moore strain; lane F: BloCeutic 
strain 
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The PsC I digests of the 6 PrV strains are shown in Figure 9. The 
TK5Â1 and IN-Fh strains differ only slightly from each other. The NVSL 
85-12 strain is somewhat similar, yet quite distinct in some of its 
pattern. It is significant that the Pst I A fragment found in the NVSL 
85-12, IH-Fh and TK5Â1 strains is not present in the 3 commercial 
vaccine strains. It has been reported previously that the Pst I Â 
fragment contains a gene that influences virulence, and that is dis­
tinct from TK (107). Although the BioCeutic strain is not closely 
related to the Norden and Pitman-Moore strains, it has also undergone a 
major change within the Pst I fragment. 
When the strains of PrV were digested with Kpn I (Figure 10), it 
was again evident that strains TK5A1 and IN-Fh are closely related, and 
that the Norden and Pitman-Moore strains are also closely related to 
each other. The NVSL 85-12 and BioCeutic strains differ from each 
other and each of the other strains in the study. 
Figure 9. Pst I digests of PrV DNA. Lane G: NVSL 85-12 strain; 
lane H: IN-Fh strain; Lane I: TK5A1 strain; lane J: Norden 
strain; Lane K: Pitman-Moore strain; Lane L: BioCeutic 
strain 
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G H I J K L 
MWx10® 
Daltons 
1.4 
1.2 
Figure 10. Kpn I digests of PrV DNA. Lane M: NVSL 85-12 strain; 
lane N: IN-Fh strain; lane 0: TK5Â1 strain; lane P: Norden 
strain; lane Q: Pitman-Moore strain; Lane R: BioCeutic 
strain 
72 
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DISCUSSION 
Â IK-negatlve mutant of FrV (TK5A1) vas isolated from the virulent 
field strain, IN-Fh, by selection in the presence of BUdR and Ara-T. 
Mutant IK5Â1 was examined for reversion to TK^; the mutation was stable 
through 10 passages in MDBK cells (Figure 3). No revertent TK* virus 
was selected from 1.2 x 10^ PFU of IK5Â1 stock culture inoculated onto 
UHK" cells and passaged 3 times in medium containing HHIG, indicating 
that if IK5A1 PrV has a reversion frequency, it is probably less than 
10-7. 
TK5A1 PrV was avirulent for adult mice when inoculated IP 
(Table 2). This was similar to the findings of Lomniczi et al. (107) 
and Tenser et al. (169) who reported that the loss of TK activity 
correlated with loss of virulence for the mouse. Studies by Field and 
Eill (47) and Fraser and Ramachandran (51) demonstrated that the nerve 
ganglia and the CNS are the principal sites of PrV replication in the 
mouse, and McCracken et al. (108) similarly documented the neuronal 
spread of PrV in calves. Studies with TK mutants of HSV suggested 
that the viral enzyme was essential for establishing a neuronal 
infection (140, 164, 167). The findings presented here support the 
role for PrV TK in determining virulence-
Mutant TK5Â1 was tested for its ability to stimulate protective 
immunity in mice and swine. As shown in Table 6, the TK5A1 strain 
provided complete protection to mice against challenge when the mice 
were vaccinated with an undiluted preparation or a 10 ^ dilution. The 
effectiveness of TK5A1 as a vaccine was clearly dose-dependent, as 
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would be expected of a live virus vaccine with limited ability to 
replicate in its host. The immunity stimulated in the mouse by IK5Â1 
may be primarily a CMI response. Levels of neutralizing antibody in 
sera from vaccinated mice were either very low or undetectable, even at 
15 DPC (Table 5). It is known that the CMI response plays the major 
role in immunity of mice to HSV infection (125, 126, 135); Sethi et al. 
(154) were able to protect mice from HSV challenge by the adoptive 
transfer of immune cytotoxic T-cells. It is likely that a similar 
mechanism was stimulated by vaccination of mice with TK5Â1. 
Use of the TK~ PrV mutant as a vaccine for swine was also exam­
ined. After vaccination in the neck muscle, 7-week-old pigs did not 
develop clinical signs of infection, and only a slight increase in body 
temperature was observed at days 7-9 post vaccination (Figure 6). 
Challenged, vaccinated pigs and nonvaccinated control pigs 
developed fevers at 3 DPC (Table 10, Figure 7), which declined by 6 
DPC. Vaccinated pigs, with the exception of pig 44, experienced mild 
clinical signs upon challenge, and recovered quickly (Table 11). Non-
vaccinated control pigs were noticeably ill at 2 DPC, and developed 
severe clinical signs, culminating in death by days 6 and 7 post 
challenge, indicating that the strain used for challenge, NVSL 85-12, 
is a highly virulent strain for swine. 
Although vaccination of pigs with the TK5A1 strain conferred good 
protection against mortality and serious morbidity, it did not prevent 
infection by the challenge virus. The clinical signs observed in 
vaccinated pigs after challenge (Table 11) were consistent with mild 
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pseudorabies. Vaccinated pigs also shed virus from the nasal cavity 
for 5 to 12 DFC (Table 12). These findings are consistent with other 
reports on the inability of modified live virus vaccines (40, 75, 114, 
115) or inactivated vaccines (40, 115, 134, 182) to prevent infection 
by virulent pseudorabies challenge virus. However, nasal swabs from 
vaccinated pigs positive for virus isolation appeared to contain less 
virus than swabs from nonvaccinated pigs. In a study by Maes et al. 
(119), vaccinated pigs shed virus for a shorter period of time than did 
nonvaccinated, challenged pigs. Maes recovered virus in nasal swabs as 
late as 19-21 DPC. 
The neutralizing antibody titers in vaccinated pigs (Table 8) were 
2- to 8-fold greater than those reported by Skoda et al. (160), Howarth 
(75) and McFerran et al. (115) in studies with the BUK strain. The 
differences noted may have been caused by a more linited ability of the 
BUK strain to replicate in the pig, or may be due to differences in the 
animals used or in the method of the virus neutralization test. 
However, considerable evidence is available that TK HSV (48, 58, 164, 
167) and PrV (169) replicate well in nonneural tissue, which may result 
in higher levels of immunity than those caused by virus strains con­
taining mutations in other loci which influence virulence. 
It was also observed that the VN titer of pig 48 did not rise 
dramatically after challenge, and pig 48 also shed virus longer than 
the other vaccinated pigs (Table 12), suggesting a relationship between 
VN titer and viral clearance. 
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The reason pig 44 did not respond to vaccination is not clear. It 
is possible that the vaccine was administered to a site less accessible 
to the immune system, or that the pig was not able to mount an adequate 
immune response because of a physiological or genetic anomaly. Pig 44 
survived 1 to 2 days longer than nonvaccinated pigs, and did not 
develop serious clinical signs until 6 DPC, indicating some resistance 
to infection. In addition, pig 44 did not exhibit signs of CNS 
infection, in contrast to nonvaccinated animals. The results suggest 
that the pig demonstrated signs of partial resistance to the challenge 
virus, but was unable to launch a full immune response because of an 
undetermined immune suppression or genetic immune deficiency. 
The 3 commercial MLV vaccine strains expressed TK activities, as 
did 2 virulent field isolates (Figure 4). Analysis of the kinetic 
behavior of TK from the vaccine and virulent strains revealed only 
minor differences in Km values (Table 3). The small differences in Km 
values probably have little biological significance. 
The Km values determined for the PrV strains are approximately 
7 to 10 fold greater than values reported for HSV (Table 13). The 
difference is perhaps due to the more stringent neurotropism of HSV, 
which is thus more dependent on viral TK activity for optimum survival 
in the host. The PrV Km values are somewhat similar to the values re­
ported for marmoset herpesvirus TK (104) and the TK from eucaryotic 
cell cytoplasm (23, 103), and considerably less than the values for 
3 of the 4 mitochondrial TKs (23, 104). 
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Table 13. Km values for thymidine of thymidine kinase from various 
sources 
Km (vm) Reference 
HSV type 1 clinical isolate 0.54* 117 
tl II II If 0.57^ 117 
II II II 11 0.29^ 117 
" " strain KOS 0.14 117 
II II II It 0.59 29 
HSV type 2 strain 333 0.35 29 
Marmoset herpesvirus 4.7 104 
Eucaryotic cell cytoplasm 2.6 103 
It tl It ® 2.72 23 
Mitochondria*^ 5.2 103 
II f 10.4 104 
II e 12.4 23 
II g 13.1 23 
following acyclovir (ACV) therapy, viral TK isolated from the 
patient had a Km value of 25.5 ym. 
^Following ACV therapy, viral TK isolated from the patient had a 
Km value of 1.96 im. 
^Following ACV therapy, viral TK isolated from the patient had a 
Km value of 1.41 ym. 
'^last cells of acute myelocytic leukemia. 
^LA9 cell culture. 
^Chick embryo cells. 
®12!TK cell culture. 
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Determination, of the Km is independent of enzyme concentration. 
The Vmax, however, is dependent on enzyme concentration, and varies 
among replications (Table 3). The 3rd replication of the BioCeutic 
strain produced much lower counts in the initial velocity assay than 
were observed during the first 2 replications. The cells from which 
the enzyme was extracted for the 3rd assay showed much less CPE after 
overnight incubation, probably due to a lower MOI, and consequently 
yielded less viral TK in the extract. The 5n value for the 3rd 
replication was very similar to those of the first 2 assays. 
Restriction enzyme (RE) analysis revealed that the Norden and 
Pitman-Moore PrV strains are closely related (Figures 8, 9, 10). The 
BioCeutic strain is significantly different in EE patterns from the 
other 5 strains examined, indicating a distant evolutionary relation­
ship. It is significant, however, that the BioCeutic strain, as well 
as the Norden and Pitman-Moore strains, lack the distinct Pst I À 
fragment that is found in the other 3 strains (Figure 9). Geek et al. 
(52, 53) observed that the absence of the Pst I A fragment was a marker 
for the Bartha K strain, and could be used to distinguish it from other 
avirulent and virulent strains of PrV. Lomniczi et al. (107) used 
marker rescue of a wildtype PrV Pst I A fragment to restore virulence 
to the Bartha strain, proving that a gene that influences virulence 
lies in that region of the genome. Very recent evidence indicates that 
a glycoprotein may be the gene product encoded in the Pst 1 A fragment 
that plays a role in determining virulence (122) and may function in 
release of virions from Infected cells (21). 
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BE analysis also revealed minor variations between the IN-Fh 
strain and the TK5Â1 TK~ mutant derived from it (Figures 8, 9, 10). 
Ben-Porat et al. (20) also noted that RE pattern differences existed 
between a TK** mutant and its parental strain. Ben-Porat reported 
reiterations of the Bam HI E fragment in DM. from the TK mutant, which 
was not observed in the parental strain pattern. Ben-Porat concluded 
that the change in the RE pattern may be related to a biological 
function associated with the loss of IK activity. In the present 
study, the BAM HI E fragment did not change after selection for a IK 
mutant. The changes in the IK5A1 RE pattern are associated with an 
increase in MW of Bam HI fragments L and N (Figure 8). Both the L and 
N fragments map within the repeat sequences of the genome (Figure 1). 
The Bam HI fragment E also maps within the repeat sequences, contiguous 
to the L and N fragments. It has been observed by Wathen and Firtle 
(178) that the repeat region is associated with minor changes in 
restriction fragment mobility; they reported that similar changes 
occurred in the Bam HI L and N fragments after passage of a strain of 
PrV in vivo. Similar changes occur in HSV (37) and equine herpes virus 
type 1 (2), anH are probably not associated with the TK gene function, 
which maps at approximately 0.45 map units (18). 
The six PrV strains included In the present study were compared 
for virulence for the mouse (Table 2). The commercial vaccine strains, 
which express TK activity similar to the virulent strains but contain a 
major deletion in the Pst I Â region of the genome, are reduced in 
virulence for the mouse approximately 2 to 10 fold, compared to the 
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NVSL 85-12 and IN-Fh strains. The TK5Â1 strain, which lacks TK activ­
ity but retains a Fst I HE pattern similar to the virulent strains, is 
avirulent for the mouse by IP inoculation. Although the gene contained 
in the Pst I A fragment of the genome influences virulence, 
particularly for swine, the TK gene obviously has a much greater 
influence on virulence. It is the belief of this author that modified 
live vaccines for PrV would be much safer if they were made deficient 
in TK activity. As noted in 2 reports (98, 174), fatal infections in 
sheep occasionally occur from the use of attenuated FrV vaccine virus, 
and in a recent incident in Illinois, one or more cattle died as the 
result of vaccination with a PrV live-virus vaccine.^ Some interest 
has been shown in vaccinating cattle (25) and dogs (133) against 
pseudorabies, but the results have not been satisfactory. It is 
possible that one or more inoculations with a TK vaccine strain, such 
as TK5A1 or a similar strain, would stimulate protective Immunity in 
these species. 
While this work was in progress, two reports appeared in the 
literature concerning the vaccination of swine with TK live-virus 
vaccines. McGregor et al. (116) vaccinated pigs with a TK mutant of 
the Kaplan (Ka) strain of PrV selected in the presence of Ara-T. The 
vaccine was effective in preventing mortality in 8-week-old pigs 
challenged with the Sullivan FrV strain. Ganglia from vaccinated 
^Dr. G. A. Erlckson, USDA, NVSL, DVL, Ames, lA, personal 
communication. 
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animals were co-cultivated with PrV-susceptible cell cultures in an 
attempt to reisolate latent vaccine virus. No vaccine virus was 
isolated. Similarly, ganglia from vaccinated and nonvaccinated animals 
taken post challenge were assayed for latent virus, and the percentage 
of reisolations was greatly reduced for the vaccinated group, indicat­
ing that vaccination with a live virus vaccine greatly reduces the 
colonization of ganglia by challenge virus. 
Kit et al. (90) produced a TK~ vaccine virus by using recombinant 
DM techniques to delete a portion of the IK gene of the BUR strain of 
PrV. The use of this approach prevents the reversion of the mutant to 
TK^, which might occur with a TR strain selected by drug resistance. 
Vaccination of swine with the TK~ BUR strain stimulated the production 
of low levels of neutralizing antibody and was effective in preventing 
mortality in animals challenged with the virulent IN-Fh strain. 
The question arises as to the relative effectiveness of a TR 
mutant of the already attenuated BUR strain which originated in central 
Europe, and has undergone countless passages in vitro since its iso­
lation, relative to a TR mutant of a virulent PrV strain isolated 
recently in the United States. It is possible that selection only for 
the TK phenotype may allow more replication in the region of Inocu­
lation than would a strain also having a deletion in the Pst I A region 
of the genome, as does the BUR strain. Greater replication might 
result in a stronger primary immune response. It is also possible that 
the BUR strain does not share all the antigenic determinants that play 
a role in the immune response to PrV strains endemic in the United 
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States. Therefore, selection of a IK strain of PrV from a region with 
endemic pseudorabies might provide a vaccine with a greater number of 
shared antigenic determinants with strains circulating in that area, 
resulting in greater effectiveness. 
In conclusion, the IK5Â1 strain may 1} be able to replicate in the 
host to a greater extent than strains derived from the Bartha or BUK 
strains, resulting in a stronger primary immune response; 2) share more 
antigenic determinants with PrV strains circulating in the United 
States than strains derived from the Bartha or BDK strains ; and 3) be 
safe for use in non-swine species. 
Further studies should be conducted on IK PrV strains derived 
from field isolates to determine whether the points listed above are 
verifiable. 
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SUMMARY 
A thymidine kinase (TK)-negative mutant of the Indiana-Funkhauser 
strain of pseudorabies virus (PrV) was isolated and examined for 
reversion to TK*. The TK~ mutant was avirulent for mice inoculated 
intraperitoneally, and for 7-week-old swine inoculated intramuscularly. 
The TK mutant stimulated protective immunity in mice and swine 
challenged with lethal doses of a virulent PrV challenge strain. 
Three commercially available modified live-virus (HLV) vaccine 
strains and 2 field isolates were determined to encode TK activity by 
thymidine plaque autoradiography. Enzyme kinetic behavior of the TK 
extracted from LMTK~ cells infected with the HLV vaccine strains and 2 
field isolates revealed only minor differences in Km values. 
The TK mutant, 2 field isolates and 3 vaccine strains were 
compared by restriction endonuclease (RE) analysis and for relative 
virulence for mice. The 3 vaccine strains were 2 to 10 fold less 
virulent for mice compared with the field isolates; in contrast, the 
TK~ mutant did not cause morbidity or mortality in mice. 
RE analysis revealed that all 3 commercial vaccine strains lacked 
the Pst I A fragment characteristic of the other strains examined. It 
was also observed that 2 of the vaccine strains, Norden and 
Pitman-Moore, are closely related, and that the BioCeutic strain 
differed significantly from the other strains examined. 
Small changes in molecular weight (MW) were observed in 2 Bam HI 
fragments of the TK~ mutant when compared to Bam HI fragments of its 
parental strain. The fragments, which were greater in MN, mapped in 
•* 
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the repeat sequences of the genome. The changes observed may be 
independent of the TK phenotype. 
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